Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants

NCT07446101 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07446101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07446101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
March 24, 2026
Completion date
February 28, 2027
Enrollment
450 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy